Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system

Critical Reviews in Immunology

Volumn 26, Issue 3, 2006, Pages 231-263

  Söderberg Nauclér, Cecilia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytomegalovirus; Immune evasion; Immune system; Inflammation; Latency; Reactivation

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR; FC RECEPTOR; GAMMA INTERFERON; GENE PRODUCT; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE COFACTOR PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; PEPTIDE; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS DNA; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE PHASE RESPONSE; AIDS PATIENT; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BIRTH DEFECT; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; CONGENITAL INFECTION; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOTHELIUM CELL; EPITHELIUM CELL; EXPERIMENTAL MOUSE; GENE IDENTIFICATION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IMMEDIATE EARLY GENE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; MACROPHAGE; MOLECULAR EVOLUTION; MONOCYTE; NATURAL KILLER CELL; NEWBORN INFECTION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; SEROPREVALENCE; STEM CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS SURVIVAL;

ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; MICE;

EID: 33746061298     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (266)

1. Britt WJ, Alford CA. Cytomegalovirus. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven Publishers; 1996; p. 2493-523.
2. Davison AJ, Dargan DJ, Stow ND. Fundamental and accessory systems in herpesviruses. Antiviral Res. 2002;56(1):1-11.
3. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261(24):3561-6.
4. Lönnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation. 1984;38(5):465-8.
5. Simmons P, Kaushansky K, Torok-Storb B. Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci U S A. 1990;87(4):1386-90.
6. Soderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E. Cytomegalovirus-induced CD13-specific autoimmunity - a possible cause of chronic graft-vs-host disease. Transplantation. 1996;61(4):600-9.
7. Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, Ruchti F, Mattison K, Altschuler Y, Nelson JA. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell. 1999;99(5):511-20.
8. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J. 1993;14 Suppl K:30-8.
9. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265(5170):391-4.
10. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335(9):624-30.
11. Valantine HA. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant. 2004;23:S187-93.
12. Rahbar A, Bostrom L, Lagerstedt U, Magnusson I, Soderberg-Naucler C, Sundqvist VA. Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2003;9(3):154-61.
13. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet. 2002;360(9345): 1557-63.
14. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170(3):998-1002.
15. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347-50.
16. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Int Med. 1993;119(9):924-35.
17. Streblow DN, Nelson JA. Models of HCMV latency and reactivation. Trends Microbiol. 2003;11(7):293-5.
18. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol. 1995;76(Pt 4):741-50.
19. Jarvis MA, Wang CE, Meyers HL, Smith PP, Corless CL, Henderson GJ, Vieira J, Britt WJ, Nelson JA. Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol. 1999;73(6):4552-60.
20. Benz C, Reusch U, Muranyi W, Brune W, Atalay R, Hengel H. Efficient downregulation of major histocompatibility complex class I molecules in human epithelial cells infected with cytomegalovirus. J Gen Virol. 2001;82(Pt 9):2061-70.
21. Esclatine A, Bellon A, Michelson S, Servin AL, Quero AM, Geniteau-Legendre M. Differentiation-dependent redistribution of heparan sulfate in epithelial intestinal Caco-2 cells leads to basolateral entry of cytomegalovirus. Virology. 2001;289(1):23-33.
22. Fish KN, Soderberg-Naucler C, Mills LK, Stenglein S, Nelson JA. Human cytomegalovirus persistently infects aortic endothelial cells. J Virol. 1998;72(7):5661-8.
23. Friedman HM, Macarak RR, MacGregor J, Kefalides NA. Virus infection of endothelial cells. J Infect Dis. 1981;2:266-73.
24. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol. 1995;76(Pt 4):741-50.
25. Read RW, Zhang JA, Ishimoto SI, Rao NA. Evaluation of the role of human retinal vascular endothelial cells in the pathogenesis of CMV retinitis. Ocul Immunol Inflamm. 1999;7(3-4):139-46.
26. Smiley ML, Mar, E.C., Huang, E.S. Cytomegalovirus infection and viral induced transformation of human endothelial cells. J Infect Dis. 1988;2:213-26.
27. Sinzger C, Schmidt K, Knapp J, Kahl M, Beck R, Waldman J, Hebart H, Einsele H, Jahn G. Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol. 1999;80(Pt 11): 2867-77.
28. Kahl M, Siegel-Axel D, Stenglein S, Jahn G, Sinzger C. Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol. 2000;74(16):7628-35.
29. Sinzger C, Kahl M, Laib K, Klingel K, Rieger P, Plachter B, Jahn G. Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry step dependent on efficient translocation to the nucleus. J Gen Virol. 2000;81(Pt 12):3021-35.
30. Slobbe-van Drunen ME, Hendrickx AT, Vossen RC, Speel EJ, van Dam-Mieras MC, Bruggeman CA. Nuclear import as a barrier to infection of human umbilical vein endothelial cells by human cytomegalovirus strain AD169. Virus Res. 1998;56(2):149-56.
31. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol. 2004;78(18):10023-33.
32. Gerna G, Percivalle E, Lilleri D, Lozza L, Fornara C, Hahn G, Baldanti F, Revello MG. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol. 2005;86(Pt 2):275-84.
33. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. Genetic content of wild-type human cytomegalovirus. J Gen Virol. 2004;85(Pt 5):1301-12.
34. Craigen JL, Grundy JE. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation. 1996;62(8):1102-8.
35. Sedmak DD, Knight DA, Vook NC, Waldman JW. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation. 1994;58(12):1379-85.
36. Burns LJ, Pooley JC, Walsh DJ, Vercellotti GM, Weber ML, Kovacs A. Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins. Transplantation. 1999;67(1):137-44.
37. 7. Bowden RA. Transfusion-transmitted cytomegalovirus infection. Hematol Oncol Clin North Am. 1995;9(1):155-66.
38. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86(9):3598-603.
39. Soderberg C, Larsson S, Bergstedt-Lindqvist S, Moller E. Identification of blood mononuclear cells permissive of cytomegalovirus infection in vitro. Transplant Proc. 1993;25(1 Pt 2):1416-8.
40. Turtinen LW, Saltzman R, Jordan MC, Haase AT. Interactions of human cytomegalovirus with leukocytes in vivo: analysis by in situ hybridization. Microbial Pathogen. 1987;3(4):287-97.
41. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72(Pt 9):2059-64.
42. Ibanez CE, Schrier R, Ghazal P, Wiley C, Nelson JA. Human cytomegalovirus productively infects primary differentiated macrophages. J Virol. 1991;65(12):6581-8.
43. Gnann JW, Jr., Ahlmen J, Svalander C, Olding L, Oldstone MB, Nelson JA. Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol. 1988;132(2):239-48.
44. Sinzger C, Plachter B, Grefte A, The Th, Jahn G. Tissue macrophages are infected by human cytomegalovirus in vivo. J Infect Dis. 1996;173(1):240-5.
45. Sinclair J, Sissons P. Latent and persistent infections of monocytes and macrophages. Intervirology. 1996;39 (5-6):293-301.
46. Weinshenker BG, Wilton S, Rice GP. Phorbol ester-induced differentiation permits productive human cytomegalovirus infection in a monocytic cell line. J Immunol. 1988;140(5):1625-31.
47. Gonczol E, Andrews PW, Plotkin SA. Cytomegalovirus replicates in differentiated but not in undifferentiated human embryonal carcinoma cells. Science. 1984;224(4645):159-61.
48. Pulliam L. Cytomegalovirus preferentially infects a monocyte derived macrophage/microglial cell in human brain cultures: neuropathology differs between strains. J Neuropathol Exp Neurol. 1991;50(4):432-40.
49. Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus- permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest. 1997;100(12):3154-63.
50. Taylor-Wiedeman J, Sissons P, Sinclair J. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol. 1994;68(3):1597-604.
51. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91(1):119-26.
52. Gredmark S, Tilburgs T, Soderberg-Naucler C. Human cytomegalovirus inhibits cytokine-induced macrophage differentiation. J Virol. 2004;78(19):10378-89.
53. Gredmark S, Soderberg-Naucler C. Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol. 2003;77(20):10943-56.
54. Gredmark S, Britt WB, Xie X, Lindbom L, Soderberg-Naucler C. Human cytomegalovirus induces inhibition of macrophage differentiation by binding to human aminopeptidase N/CD13. J Immunol. 2004;173(8):4897-907.
55. Soderberg C, Giugni TD, Zaia JA, Larsson S, Wahlberg JM, Moller E. CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol. 1993;67(11):6576-85.
56. Riegler S, Hebart H, Einsele H, Brossart P, Jahn G, Sinzger C. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol. 2000;81(Pt 2):393-9.
57. Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol. 2003;77(13):7563-74.
58. Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunay T, Houles C, Fieschi F, Arenzana-Seisdedos F, Moreau JF, Dechanet-Merville J. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity. 2002;17(5):653-64.
59. Kondo K, Xu J, Mocarski ES. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci U S A. 1996;93(20):11137-42.
60. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A. 1994;91(25):11879-83.
61. Sindre H, Tjoonnfjord GE, Rollag H, Ranneberg-Nilsen T, Veiby OP, Beck S, Degre M, Hestdal K. Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells. Blood. 1996;88(12):4526-33.
62. von Laer D, Meyer-Koenig U, Serr A, Finke J, Kanz L, Fauser AA, Neumann-Haefelin D, Brugger W, Hufert FT. Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood. 1995;86(11):4086-90.
63. Kondo K, Xu J, Mocarski ES. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci U S A. 1996;93(20):11137-42.
64. Slobedman B, Stern JL, Cunningham AL, Abendroth A, Abate DA, Mocarski ES. Impact of human cytomegalovirus latent infection on myeloid progenitor cell gene expression. J Virol. 2004;78(8):4054-62.
65. Slobedman B, Mocarski ES, Arvin AM, Mellins ED, Abendroth A. Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Blood. 2002;100(8):2867-73.
66. Jenkins C, Abendroth A, Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol. 2004;78(3):1440-7.
67. White KL, Slobedman B, Mocarski ES. Human cytomegalovirus latency-associated protein pORF94 is dispensable for productive and latent infection. J Virol. 2000;74(19):9333-7.
68. Soderberg-Naucler C, Streblow DN, Fish KN, Allan-Yorke J, Smith PP, Nelson JA. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol. 2001;75(16):7543-54.
69. Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, Syrbe U, Kruger DH, von Baehr R, Volk HD. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343(8892):268-9.
70. Humar A, St Louis P, Mazzulli T, McGeer A, Lipton J, Messner H, MacDonald KS. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. J Infect Dis. 1999;179(2):484-8.
71. Prosch S, Staak K, Stein J, Liebenthal C, Stamminger T, Volk HD, Kruger DH. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. Virol. 1995;208(1):197-206.
72. Miller W, Flynn P, McCullough J, Balfour H Jr, Goldman A, Haake R, McGlave P, Ramsay N, Kersey J. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood. 1986;67(4):1162-7.
73. Hummel M, Zhang Z, Yan S, DePlaen I, Golia P, Varghese T, Thomas G, Abecassis MI. Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J Virol. 2001;75(10):4814-22.
74. Simon CO, Seckert CK, Dreis D, Reddehase MJ, Grzimek NK. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol. 2005;79(1):326-40.
75. Hanson LK, Slater JS, Karabekian Z, Ciocco-Schmitt G, Campbell AE. Products of US22 genes M140 and M141 confer efficient replication of murine cytomegalovirus in macrophages and spleen. J Virol. 2001;75(14):6292-302.
76. Asadullah K, Prosch S, Audring H, Buttnerova I, Volk HD, Sterry W, Docke WD. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol. 1999;141(1):94-102.
77. Docke WD, Kiessling C, Worm M, Friedrich M, Pruss A, Weitz M, Prosch S, Kern F, Volk HD, Sterry W, Asadullah K. Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis. Br J Dermatol. 2003;148(5):954-63.
78. van den Berg AP, Klompmaker IJ, Haagsma EB, Peeters PM, Meerman L, Verwer R, The TH, Slooff MJ. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant. 1996;10(2):224-31.
79. Cook CH, Zhang Y, McGuinness BJ, Lahm MC, Sedmak DD, Ferguson RM. Infra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis. 2002;185(10):1395-400.
80. Mehta SK, Stowe RP, Feiveson AH, Tyring SK, Pierson DL. Reactivation and shedding of cytomegalovirus in astronauts during spaceflight. J Infect Dis. 2000;182(6):1761-4.
81. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med. 2001;29(3):541-7.
82. Prosch S, Wendt CE, Reinke P, Priemer C, Oppert M, Kruger DH, Volk HD, Docke WD. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology. 2000;272(2):357-65.
83. Moss P, Khan N. CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol. 2004;65(5):456-64.
84. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003;101(7):2686-92.
85. Reddehase MJ. The immunogenicity of human and murine cytomegaloviruses. Curr Op Immunol. 2000;12(4):390-6.
86. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991; 78(5):1373-80.
87. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238-41.
88. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant. 1996;18(2): 347-53.
89. Reddehase MJ, Podlech J, Grzimek NK. Mouse models of cytomegalovirus latency: overview. J Clin Virol. 2002;25 Suppl 2:S23-36.
90. Pavic I, Polic B, Crnkovic I, Lucin P, Jonjic S, Koszinowski UH. Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol. 1993;74(Pt 10):2215-23.
91. Le Roy E, Baron M, Faigle W, Clement D, Lewinsohn DM, Streblow DN, Nelson JA, Amigorena S, Davignon JL. Infection of APC by human cytomegalovirus controlled through recognition of endogenous nuclear immediate early protein 1 by specific CD4(+) T lymphocytes. J Immunol. 2002;169(3):1293-301.
92. Bitmansour AD, Waldrop SL, Pitcher CJ, Khatamzas E, Kern F, Maino VC, Picker LJ. Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus. J Immunol. 2001;167(3):1151-63.
93. Beninga J, Kropff B, Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cells. J Gen Virol. 1995;76:153-60.
94. Davignon JL, Castanie P, Yorke JA, Gautier N, Clement D, Davrinche C. Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol. 1996;70(4):2162-9.
95. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238-41.
96. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005;201(7):1031-6.
97. Pahl-Seibert MF, Juelch M, Podlech J, Thomas D, Deegen P, Reddehase MJ, Holtappels R. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol. 2005;79(9):5400-13.
98. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001;2(3):255-60.
99. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
100. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5(4):405-11.
101. Varani S, Frascaroli G, Homman-Loudiyi M, Feld S, Landini MP, Soderberg-Naucler C. Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5. J Leukoc Biol. 2005;77(2):219-28.
102. Arrode G, Davrinche C. Dendritic cells and HCMV cross-presentation. Curr Top Microbiol Immunol. 2003;276:277-94.
103. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. New Eng J Med. 1989;320(26):1731-5.
104. Quinnan G, Jr., Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R, Burns WH. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982;307(1):7-13.
105. Bukowski JF, Woda BA, Habu S, Okumura K, Welsh RM. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol. 1983;131(3):1531-8.
106. Salazar-Mather TP, Hokeness KL. Calling in the troops: regulation of inflammatory cell trafficking through innate cytokine/chemokine networks. Viral Immunol. 2003;16(3):291-306.
107. Vidal SM, Lanier LL. NK cell recognition of mouse cytomegalovirus- infected cells. Curr Top Microbiol Immunol. 2006;298:183-206.
108. Robbins SH, Tessmer MS, Mikayama T, Brossay L. Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection. J Immunol. 2004;173(1):259-66.
109. Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA. Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol. 2003;4(2):175-81.
110. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science. 2002;296(5571):1323-6.
111. Scalzo AA, Fitzgerald NA, Wallace CR, Gibbons AE, Smart YC, Burton RC, Shellam GR. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol. 1992;149(2):581-9.
112. Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. Specific and nonspecific NK cell activation during virus infection. Nat Immunol. 2001;2(10):951-6.
113. Rodriguez M, Sabastian P, Clark P, Brown MG. Cmv1-independent antiviral role of NK cells revealed in murine cytomegalovirus-infected New Zealand White mice. J Immunol. 2004;173(10):6312-8.
114. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, Scalzo AA, Davis Poynter NJ. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature. 1997;386(6624):510-4.
115. Bubic I, Wagner M, Krmpotic A, Saulig T, Kim S, Yokoyama WM, Jonjic S, Koszinowski UH. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol. 2004;78(14):7536-44.
116. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-93.
117. Chin KC, Cresswell P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci U S A. 2001;98(26):15125-30.
118. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Int Med. 1987;106(1):12-8.
119. Landini MP, La Placa M. Humoral immune response to human cytomegalovirus proteins: a brief review. Comp Immunol Microbiol Inf Dis. 1991;14(2):97-105.
120. Urban M, Winkler T, Landini MP, Britt W, Mach M. Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus. J Infect Dis. 1994;169(1):83-90.
121. McLean GR, Olsen OA, Watt IN, Rathanaswami P, Leslie KB, Babcook JS, Schrader JW. Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. J Immunol. 2005;174(8):4768-78.
122. Grigoleit U, Riegler S, Einsele H, Laib Sampaio K, Jahn G, Hebart H, Brossart P, Frank F, Sinzger C. Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte-derived immature dendritic cells. Br J Haematol. 2002;119(1):189-98.
123. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood. 2002;99(8):2913-21.
124. Beck K, Meyer-Konig U, Weidmann M, Nern C, Hufert FT. Human cytomegalovirus impairs dendritic cell function: a novel mechanism of human cytomegalovirus immune escape. Eur J Immunol. 2003;33(6):1528-38.
125. Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood. 2004;103(11):4207-15.
126. Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H, Schonrich G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity. 2001;15(6):997-1009.
127. Moutaftsi M, Brennan P, Spector SA, Tabi Z. Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. J Virol. 2004;78(6):3046-54.
128. Chang WL, Baumgarth N, Yu D, Barry PA. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol. 2004;78(16):8720-31.
129. Raftery MJ, Wieland D, Gronewald S, Kraus AA, Giese T, Schonrich G. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J Immunol. 2004;173(5):3383-91.
130. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 1996;383(6602):720-2.
131. Story CM, Furman MH, Ploegh HL. The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Proc Natl Acad Sci U S A. 1999;96(15):8516-21.
132. Jones TR, Sun L. Human cytomegalovirus Us2 destabilizes major histocompatibility complex class I heavy chains. J Virol. 1997;71(4):2970-9.
133. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature. 1996;384(6608):432-8.
134. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL, Wiley DC. Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc Natl Acad Sci U S A. 2001;98(12):6794-9.
135. Tortorella D, Story CM, Huppa JB, Wiertz EJ, Jones TR, Bacik I, Bennink JR, Yewdell JW, Ploegh HL. Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in redox potential. J Cell Biol. 1998;142(2):365-76.
136. Furman MH, Ploegh HL, Tortorella D. Membrane-specific, host-derived factors are required for US2-and US11-mediated degradation of major histocompatibility complex class I molecules. J Biol Chem. 2002;277(5):3258-67.
137. Kikkert M, Hassink G, Barel M, Hirsch C, van der Wal FJ, Wiertz E. Ubiquitination is essential for human cytomegalovirus US11-mediated dislocation of MHC class I molecules from the endoplasmic reticulum to the cytosol. Biochem J. 2001;358(Pt 2):369-77.
138. Tirosh B, Iwakoshi NN, Lilley BN, Lee AH, Glimcher LH, Ploegh HL. Human cytomegalovirus protein US11 provokes an unfolded protein response that may facilitate the degradation of class I major histocompatibility complex products. J Virol. 2005;79(5):2768-79.
139. Hegde NR, Johnson DC. Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells. J Virol. 2003;77(17):9287-94.
140. Rehm A, Engelsberg A, Tortorella D, Korner IJ, Lehmann I, Ploegh HL, Hopken UE. Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells. J Virol. 2002;76(10):5043-50.
141. Gewurz BE, Wang EW, Tortorella D, Schust DJ, Ploegh HL. Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. J Virol. 2001;75(11):5197-204.
142. Schust DJ, Tortorella D, Seebach J, Phan C, Ploegh HL. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J Exp Med. 1998;188(3):497-503.
143. Barel MT, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F, Wiertz EJ. Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J Immunol. 2003;171(12):6757-65.
144. Park B, Oh H, Lee S, Song Y, Shin J, Sung YC, Hwang SY, Ahn K. The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US)2, US3, US6, and US11 gene products. J Immunol. 2002;168(7):3464-9.
145. Pizzato N, Garmy-Susini B, Le Bouteiller P, Lenfant F. Differential down-modulation of HLA-G and HLA-A2 or -A3 cell surface expression following human cytomegalovirus infection. J Reprod Immunol. 2004;62(1-2):3-15.
146. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A. 1996;93(21):11327-33.
147. Gruhler A, Peterson PA, Fruh K. Human cytomegalovirus immediate early glycoprotein US3 retains MHC class I molecules by transient association. Traffic. 2000;1(4):318-25.
148. Park B, Kim Y, Shin J, Lee S, Cho K, Fruh K, Ahn K. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity. 2004;20(1):71-85.
149. Furman MH, Dey N, Tortorella D, Ploegh HL. The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J Virol. 2002;76(22):11753-6.
150. Tirabassi RS, Ploegh HL. The human cytomegalovirus US8 glycoprotein binds to major histocompatibility complex class I products. J Virol. 2002;76(13):6832-5.
151. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, Peterson PA, Yang Y, Fruh K. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997;6(5):613-21.
152. Hengel H, Koopmann JO, Flohr T, Muranyi W, Goulmy E, Hammerling GJ, Koszinowski UH, Momburg F. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity. 1997;6(5):623-32.
153. Hewitt EW, Gupta SS, Lehner PJ. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J. 2001;20(3):387-96.
154. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci U S A. 1997;94(13):6904-9.
155. Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H, Riddell SR. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood. 2004;104(4):1075-82.
156. Wagner M, Gutermann A, Podlech J, Reddehase MJ, Koszinowski UH. Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J Exp Med. 2002;196(6):805-16.
157. Wagner M, Ruzsics Z, Koszinowski UH. Herpesvirus genetics has come of age. Trends Microbiol. 2002;10(7):318-24.
158. Kavanagh DG, Gold MC, Wagner M, Koszinowski UH, Hill AB. The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med. 2001;194(7): 967-78.
159. Kavanagh DG, Koszinowski UH, Hill AB. The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi compartment. J Immunol. 2001;167(7):3894-902.
160. Kleijnen MF, Huppa JB, Lucin P, Mukherjee S, Farrell H, Campbell AE, Koszinowski UH, Hill AB, Ploegh HL. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 1997;16(4):685-94.
161. Reusch U, Muranyi W, Lucin P, Burgert HG, Hengel H, Koszinowski UH. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 1999;18(4):1081-91.
162. Ziegler H, Thale R, Lucin P, Muranyi W, Flohr T, Hengel H, Farrell H, Rawlinson W, Koszinowski UH. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity. 1997;6(1):57-66.
163. Holtappels R, Podlech J, Pahl-Seibert MF, Julch M, Thomas D, Simon CO, Wagner M, Reddehase MJ. Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J Exp Med. 2004;199(1):131-6.
164. Gold MC, Munks MW, Wagner M, Koszinowski UH, Hill AB, Fling SP. The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J Immunol. 2002;169(1):359-65.
165. Krmpotic A, Messerle M, Crnkovic-Mertens I, Polic B, Jonjic S, Koszinowski UH. The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med. 1999;190(9):1285-96.
166. Miller DM, Rahill BM, Boss JM, Lairmore MD, Durbin JE, Waldman JW, Sedmak DD. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med. 1998;187(5):675-83.
167. Odeberg J, Plachter B, Branden L, Soderberg-Naucler C. Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain. Blood. 2003; 101(12):4870-7.
168. Odeberg J, Soderberg-Naucler C. Reduced expression of HLA class II molecules and Iinterleukin-10- and transforming growth factor beta1-independent suppression of T-cell proliferation in human cytomegalovirus-infected macrophage cultures. J Virol. 2001;75(11):5174-81.
169. Tomazin R, Boname J, Hegde NR, Lewinsohn DM, Altschuler Y, Jones TR, Cresswell P, Nelson JA, Riddell SR, Johnson DC. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med. 1999;5(9):1039-43.
170. Chevalier MS, Daniels GM, Johnson DC. Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation. J Virol. 2002;76(16):8265-75.
171. Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, Johnson DC. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002;76(21):10929-41.
172. Miller DM, Zhang Y, Rahill BM, Kazor K, Rofagha S, Eckel JJ, Sedmak DD. Human cytomegalovirus blocks interferon-gamma stimulated up-regulation of major histocompatibility complex class I expression and the class I antigen processing machinery. Transplantation. 2000;69(4):687-90.
173. Zimmermann A, Trilling M, Wagner M, Wilborn M, Bubic I, Jonjic S, Koszinowski U, Hengel H. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med. 2005;201(10):1543-53.
174. Heise MT, Pollock JL, O'Guin A, Barkon ML, Bormley S, Virgin HW IV. Murine cytomegalovirus infection inhibits IFN gamma-induced MHC class II expression on macrophages: the role of type I interferon. Virology. 1998;241(2):331-44.
175. Buchmeier NA, Cooper NR. Suppression of monocyte functions by human cytomegalovirus. Immunology. 1989;66(2):278-83.
176. Schrier RD, Rice GP, Oldstone MB. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis. 1986;153(6):1084-91.
177. Booss J, Wheelock EF. Progressive inhibition of T-cell function preceding clinical signs of cytomegalovirus infection in mice. J Infect Dis. 1977;135(3):478-81.
178. Booss J, Wheelock EF. Role of viremia in the suppression of T-cell function during murine cytomegalovirus infection. Infect Immun. 1977;17(2):378-81.
179. Kapasi K, Rice GP. Cytomegalovirus infection of peripheral blood mononuclear cells: effects on interleukin-1 and -2 production and responsiveness. J Virol. 1988;62(10):3603-7.
180. Carney WP, Hirsch MS. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis. 1981;144 (1):47-54.
181. Wahren B, Ljungman P, Paulin T, Ringden O. Enhancive and suppressive effects of cytomegalovirus on human lymphocyte responses in vitro. J Virol. 1986;58(3):909-13.
182. Timon M, Arnaiz-Villena A, Ruiz-Contreras J, Ramos-Amador JT, Pacheco A, Regueiro JR. Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection. Clin Exp Immunol. 1993;94(1):38-42.
183. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A. 2000;97(4):1695-700.
184. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, Schall TJ. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol. 2002;76(3):1285-92.
185. Nokta MA, Hassan MI, Loesch K, Pollard RB. Human cytomegalovirus-induced immunosuppression. Relationship to tumor necrosis factor-dependent release of arachidonic acid and prostaglandin E2 in human monocytes. J Clin Invest. 1996;97(11):2635-41.
186. Noraz N, Lathey JL, Spector SA. Human cytomegalovirus-associated immunosuppression is mediated through interferon-alpha. Blood. 1997;89(7):2443-52.
187. Cerboni C, Mousavi-Jazi M, Linde A, Soderstrom K, Brytting M, Wahren B, Karre K, Carbone E. Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol. 2000; 164(9):4775-82.
188. Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, Phillips JH, Lanier LL. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med. 1998;187(10):1681-7.
189. Reyburn HT, Mandelboim O, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature. 1997;386(6624):514-7.
190. Rolle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Soderberg-Naucler C, Cosman D, Karre K, Cerboni C. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol. 2003;171(2):902-8.
191. Vales-Gomez M, Browne H, Reyburn HT. Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells. BMC Immunol. 2003;4(1):4.
192. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, Rammensee HG, Steinle A. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol. 2003;33(1):194-203.
193. Bandyopadhyay S, Oh SH, Michelson S, Miller DS, Virelizier JL, Starr SE. Natural killing of fibroblasts infected with low-passage clinical isolates of human cytomegalovirus. Clin Exp Immunol. 1988;73(1):11-6.
194. Bandyopadhyay S, Perussia B, Trinchieri G, Miller DS, Starr SE. Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts. J Exp Med. 1986;164(1):180-95.
195. Falk CS, Mach M, Schendel DJ, Weiss EH, Hilgert I, Hahn G. NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol. 2002;169(6):3257-66.
196. Odeberg J, Cerboni C, Browne H, Karre K, Moller E, Carbone E, Soderberg-Naucler C. Human cytomegalovirus (HCMV)-infected endothelial cells and macrophages are less susceptible to natural killer lysis independent of the downregulation of classical HLA class I molecules or expression of the HCMV class I homologue, UL18. Scand J Immunol. 2002;55(2):149-61.
197. Cerboni C, Mousavi-Jazi M, Wakiguchi H, Carbone E, Karre K, Soderstrom K. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol. 2001;31(10):2926-35.
198. Fletcher JM, Prentice HG, Grundy JE. Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced downregulation of cell surface class I HLA. J Immunol. 1998;161(5):2365-74.
199. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science. 2000;287(5455):1031.
200. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature. 1988;331(6153):269-72.
201. Browne H, Smith G, Beck S, Minson T. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature. 1990;347(6295):770-2.
202. Fahnestock ML, Johnson JL, Feldman RM, Neveu JM, Lane WS, Bjorkman PJ. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity. 1995;3(5):583-90.
203. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7(2):273-82.
204. Cretney E, Degli-Esposti MA, Densley EH, Farrell HE, Davis-Poynter NJ, Smyth MJ. m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J Exp Med. 1999;190(3):435-44.
205. Kubota A, Kubota S, Farrell HE, Davis-Poynter N, Takei F. Inhibition of NK cells by murine CMV-encoded class I MHC homologue m144. Cell Immunol. 1999;191(2):145-51.
206. Carr WH, Little AM, Mocarski E, Parham P. NK cell-mediated lysis of autologous HCMV-infected skin fibroblasts is highly variable among NK cell clones and polyclonal NK cell lines. Clin Immunol. 2002;105(2):126-40.
207. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123-33.
208. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol. 2002;168(2):671-9.
209. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau AM, Ulrich D, Armitage R. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol. 2001;31(5):1428-37.
210. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol. 2003;170(8):4196-200.
211. Zou Y, Bresnahan W, Taylor RT, Stastny P. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol. 2005;174(5):3098-104.
212. Odeberg J, Browne H, Metkar S, Froelich CJ, Branden L, Cosman D, Soderberg-Naucler C. The human cytomegalovirus protein UL16 mediates increased resistance to natural killer cell cytotoxicity through resistance to cytolytic proteins. J Virol. 2003;77(8):4539-45.
213. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 2000;12(6):721-7.
214. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1(2):119-26.
215. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol. 2002;169(8):4079-83.
216. Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T, Polic B, Bubic I, Kriegeskorte A, Pernjak-Pugel E, Messerle M, Hengel H, Busch DH, Koszinowski UH, Jonjic S. NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med. 2005;201(2):211-20.
217. Hasan M, Krmpotic A, Ruzsics Z, Bubic I, Lenac T, Halenius A, Loewendorf A, Messerle M, Hengel H, Jonjic S, Koszinowski UH. Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol. 2005;79(5):2920-30.
218. Krmpotic A, Busch DH, Bubic I, Gebhardt F, Hengel H, Hasan M, Scalzo AA, Koszinowski UH, Jonjic S. MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol. 2002;3(6):529-35.
219. Oliveira SA, Park SH, Lee P, Bendelac A, Shenk TE. Murine cytomegalovirus m02 gene family protects against natural killer cell-mediated immune surveillance. J Virol. 2002;76(2):885-94.
220. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, Weiss EH. The human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell mediated Lysis. J Immunol. 2000;164:5019-22.
221. Onno M, Pangault C, Le Friec G, Guilloux V, Andre P, Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol. 2000;164(12):6426-34.
222. Pazmany L, Mandelboim O, Vales Gomez M, Davis DM, Reyburn HT, Strominger JL. Protection from natural killer cell mediated lysis by HLA G expression on target cells. Science. 1996.;274:792-5.
223. Wang EC, McSharry B, Retiere C, Tomasec P, Williams S, Borysiewicz LK, Braud VM, Wilkinson GW. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci U S A. 2002;99(11):7570-5.
224. Llano M, Guma M, Ortega M, Angulo A, Lopez-Botet M. Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur J Immunol. 2003;33(10):2744-54.
225. Ulbrecht M, Hofmeister V, Yuksekdag G, Ellwart JW, Hengel H, Momburg F, Martinozzi S, Reboul M, Pla M, Weiss EH. HCMV glycoprotein US6 mediated inhibition of TAP does not affect HLA-E dependent protection of K-562 cells from NK cell lysis. Hum Immunol. 2003;64(2):231-7.
226. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, McSharry BP, Morris RJ, Llewellyn-Lacey S, Rickards C, Nomoto A, Sinzger C, Wilkinson GW. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol. 2005;6(2):181-8.
227. Reboredo M, Greaves RF, Hahn G. Human cytomegalovirus proteins encoded by UL37 exon 1 protect infected fibroblasts against virus-induced apoptosis and are required for efficient virus replication. J Gen Virol. 2004;85(Pt 12):3555-67.
228. Colberg-Poley AM, Patel MB, Erezo DP, Slater JE. Human cytomegalovirus UL37 immediate-early regulatory proteins traffic through the secretory apparatus and to mitochondria. J Gen Virol. 2000;81(Pt 7):1779-89.
229. Goldmacher VS, Barde LM, Skaletskaya A, Dionne CA, Kedersha NL, Vater CA, Han JW, Lutz RJ, Watanabe S, Cahir McFarland ED, Kieff ED, Mocarski ES, Chittenden T. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Nad Acad Sci U S A. 1999;96(22):12536-41.
230. Benedict CA, Butrovich KD, Lurain NS, Corbeil J, Rooney I, Schneider P, Tschopp J, Ware CF. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol. 1999;162(12):6967-70.
231. Skaletskaya A, Barde LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Nad Acad Sci U S A. 2001;98(14):7829-34.
232. Zhu H, Shen Y, Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol. 1995;69(12):7960-70.
233. MacCormac LP, Grundy JE. Human cytomegalovirus induces an Fc gamma receptor (Fc gammaR) in endothelial cells and fibroblasts that is distinct from the human cellular Fc gammaRs. J Infect Dis. 1996;174(6):1151-61.
234. Lilley BN, Ploegh HL, Tirabassi RS. Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein. J Virol. 2001;75(22):11218-21.
235. Atalay R, Zimmermann A, Wagner M, Borst E, Benz C, Messerle M, Hengel H. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol. 2002;76(17):8596- 608.
236. Dubin G, Socolof E, Frank I, Friedman HM. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol. 1991;65(12):7046-50.
237. Spiller OB, Hanna SM, Devine DV, Tufaro F. Neutralization of cytomegalovirus virions: the role of complement. J Infect Dis. 1997;176(2):339-47.
238. Spiller OB, Morgan BP, Tufaro F, Devine DV. Altered expression of host encoded complement regulators on human cytomegalovirus infected cells. Eur J Immunol. 1996;26(7):1532-8.
239. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol. 1995;155(9):4376-81.
240. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259(3):219-46.
241. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003;77(8):4588-96.
242. Iwamoto GK, Monick MM, Clark BD, Auron PE, Stinski MF, Hunninghake GW. Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest. 1990;85(6):1853-7.
243. Craigen JL, Yong KL, Jordan NJ, MacCormac LP, Westwick J, Akbar AN, Grundy JE. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology. 1997;92(1):138-45.
244. Haagmans BL, Stals FS, van der Meide PH, Bruggeman CA, Horzinek MC, Schijns VE. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus. J Virol. 1994;68(4):2297-304.
245. Stein J, Volk HD, Liebenthal C, Kruger DH, Prosch S. Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol. 1993;74(Pt 11):2333-8.
246. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 1989;8(13):4251-8.
247. Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol. 1995;69(9):5391-400.
248. Laegreid A, Medvedev A, Nonstad U, Bombara MP, Ranges G, Sundan A, Espevik T. Tumor necrosis factor receptor p75 mediates cell- specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem. 1994;269(10):7785-91.
249. Prosch S, Heine AK, Volk HD, Kruger DH. CCAAT/enhancer-binding proteins alpha and beta negatively influence the capacity of tumor necrosis factor alpha to up-regulate the human cytomegalovirus IE1/2 enhancer/promoter by nuclear factor kappaB during monocyte differentiation. J Biol Chem. 2001;276(44):40712- 20.
250. Baillie J, Sahlender DA, Sinclair JH. Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-alpha) signaling by targeting the 55-kilodalton TNF-alpha receptor. J Virol. 2003;77(12):7007-16.
251. Simmen KA, Singh J, Luukkonen BG, Lopper M, Bittner A, Miller NE, Jackson MR, Compton T, Fruh K. Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc Natl Acad Sci U S A. 2001;98(13):7140-5.
252. Boehme KW, Singh J, Perry ST, Compton T. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol. 2004;78(3):1202-11.
253. Abate DA, Watanabe S, Mocarski ES. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol. 2004;78(20):10995-1006.
254. Penfold ME, Dairaghi DJ, Duke GM, Saederup N, Mocarski ES, Kemble GW, Schall TJ. Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci U S A. 1999;96(17):9839-44.
255. Gerna G, Percivalle E, Baldanti F, Sozzani S, Lanzarini P, Genini E, Lilleri D, Revello MG. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol. 2000;74(12):5629-38.
256. Fleming P, Davis-Poynter N, Degli-Esposti M, Densley E, Papadimitriou J, Shellam G, Farrell H. The murine cytomegalovirus chemokine homolog, m131/129, is a determinant of viral pathogenicity. J Virol. 1999;73(8):6800-9.
257. Saederup N, Lin YC, Dairaghi DJ, Schall TJ, Mocarski ES. Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. Proc Natl Acad Sci U S A. 1999;96(19):10881-6.
258. Neote K, DiGregorio D, Mak JY, Honik R, Schall TJ. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell. 1993;72(3):415-25.
259. Kuhn DE, Beall CJ, Kolattukudy PE. The cytomegalovirus US28 protein binds multiple CC chemokines with high affinity. Biochem Biophys Res Commun. 1995;211(1):325-30.
260. Billstrom MA, Johnson GL, Avdi NJ, Worthen GS. Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection. J Virol. 1998;72(7):5535-44.
261. Pleskoff O, Treboute C, Brelot A, Heveker N, Seman M, Alizon M. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science. 1997;276(5320):1874-8.
262. Bodaghi B, Jones TR, Zipeto D, Vita C, Sun L, Laurent L, Arenzana-Seisdedos F, Virelizier JL, Michelson S. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med. 1998;188(5):855-66.
263. Beisser PS, Vink C, Van Dam JG, Grauls SJ, Vanherle SJ, Bruggeman CA. The R33 G protein coupled receptor gene oi rat cytomegalovims plays an essential role in the pathogenesis of viral infection. J Virol. 1998;72(3):2352-63.
264. Davis-Poynter NJ, Lynch DM, Vally H, Shellam GR, Rawlinson WD, Barrell BG, Farrell HE. Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus. J Virol. 1997;71(2):1521-9.
265. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273-82.
266. Rinaldo CR, Jr., Carney WP, Richter BS, Black PH, Hirsch MS. Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis. 1980;141(4):488-95.